83results about How to "Improve adverse reactions" patented technology

It is an object of the present invention to provide a method for removing the metal element from the semiconductor film which is different from the conventional gettering step for removing the metal element from the semiconductor film.In the present invention, when Ni element (Ni) is used as the metal element and a silicon-based film (referred to as a silicon film) is used as the semiconductor film, nickel silicide segregates in the ridge formed in the silicon film by irradiating the pulsed laser light. Next, etching solution of hydrofluoric acid based etchant is used to remove the nickel silicide segregated in the ridge. When the surface of the semiconductor film is rough after removing the metal element by means of etching, the laser light may be irradiated to the semiconductor film under the insert atmosphere to flatten the surface thereof.

The present invention related to a lift-off structure adapted to a substrate having a photoelectric device, the structure comprising: a buffer layer, forming on the substrate; an upper sacrificial layer, forming on the buffer layer; an etch stop layer, forming on the upper sacrificial layer, and the photoelectric device structure forming on the etch stop layer.

Disclosed are a battery package and a method for charging and discharging secondary batteries including nickel hydrogen batteries by refreshing and suppressing inactivity of the batteries. More concretely, battery package (101) comprises a group of batteries having a plurality of connected secondary batteries, each forming a unit battery, a plurality of sensors for detecting a temperature and a voltage, a display device for displaying a condition of the group of batteries, a switch for controlling charge and discharge of the group of batteries, and an operational control circuit (4) for generating a signal based on signals input from the plurality of sensors to make the display device display the condition of the group of batteries and to activate the switch, wherein the battery package (101) is provided with refreshing demand display device (13) for displaying a need to initiate a refreshing charge and discharge, and it uses the method of carrying out the refreshing charge and discharge automatically when a recovery voltage of the secondary batteries does not exceed a predetermined voltage after a lapse of a predetermined time from a moment when the secondary batteries come to a final discharge voltage. This invention can thus carry out the refreshing charge and discharge even for secondary batteries that become inactive after having been left unused for a long time.

The invention discloses application of an interleukin-1 receptor antagonist in the field of biological medicine and a medicinal composition thereof. The invention discloses application of the following (a) or (b) protein in preparing a medicament for preventing or treating intestinal mucosal epithelial cell injury disease: (a) the protein of which an amino acid sequence is shown in SEQ ID NO: 1; and (b) the protein which has at least 70 percent of homology with the amino acid sequence in the (a) and has the effect of preventing or treating the intestinal mucosal epithelial cell injury disease. The proteins can effectively prevent or treat the intestinal mucosal epithelial cell injury disease, can reduce diarrhea and body weight loss, and reduce and improve the injury of chemotherapy on small intestines.

A tetracycline salt comprising a tetracycline and an organic acid wherein the organic acid is oxalic acid or maleic acid is provided. The tetracycline is preferably doxycycline, minocycline, sancycline, lymecycline, tetracycline or demeclocycline, and preferred salts include oxycycline maleate, minocycline oxalate, tetracycline oxalate, demeclocycline maleate, demeclocycline oxalate, sancycline maleate, lymecycline maleate, or lymecycline oxalate. A pharmaceutical formulation comprising a tetracycline salt according to the invention is also provided, as is a medical device having coated thereon a salt or pharmaceutical formulation according to the invention. A salt of the invention, or a formulation of the invention are also provided for use as medicaments, particularly for use in the treatment or prevention of an inflammation and / or an infection. There is also provided a method of preparing a tetracycline salt, which method comprises reacting a tetracycline base with an excess of an organic acid in a solvent.

The present invention related to a lift-off structure adapted to a substrate having a photoelectric device, the structure comprising: a buffer layer, forming on the substrate; an upper sacrificial layer, forming on the buffer layer; an etch stop layer, forming on the upper sacrificial layer, and the photoelectric device structure forming on the etch stop layer.

The present invention provides a medicine injection of recombinant human erythropoietin. It contains no human serum albumin, and uses a certain quantity of the derivative of polyoxyethylene sorbitan fatty acid as stabilizing agent. It can be more safely used for curing or preventing diseases applicable to erythropoietin.

A hub of intelligent Internet of Things (IoT) for performing a light therapy using light irradiated by a light output device. The hub of intelligent IoT includes a sleep disorder reading unit determining whether a sleep disorder has occurred based on sleep pattern information; a control signal generator generating a control signal for controlling the light output device when it is determined that the sleep disorder has occurred; and a communication interface unit providing the control signal to the light output device. At least one device implementing the method of providing the intelligent voice recognition model may be associated with an artificial intelligence module, a unmanned aerial vehicle (UAV), a robot, an augmented reality (AR) device, a virtual reality (VR) device, devices related to 5G services, and the like.